Chronic migraine
Conditions
Brief summary
Difference in change from baseline in the mean monthly headache days at weeks 5 – 8 post intervention in the treatment versus the placebo group
Detailed description
Difference in occurrence of adverse events and serious adverse events in the treatment versus the placebo group, Difference in change from baseline in the mean monthly migraine days* in the treatment versus the placebo group, Difference in number of treatment responders (≥ 30% reduction in mean monthly headache days at weeks 5 – 8 post-intervention compared to baseline) in the treatment versus the placebo group., Difference in change from baseline in the mean monthly headache intensity in the treatment versus the placebo group., Difference in change from baseline in the mean monthly occurrence of cumulative hours per 28 days of moderate/severe pain in the treatment versus the placebo group., Difference in change from baseline in the mean monthly number of days with rescue medication in the treatment versus the placebo group., Migraine specific quality of life questionnaire
Interventions
Sponsors
St. Olavs Hospital HF
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in change from baseline in the mean monthly headache days at weeks 5 – 8 post intervention in the treatment versus the placebo group | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in occurrence of adverse events and serious adverse events in the treatment versus the placebo group, Difference in change from baseline in the mean monthly migraine days* in the treatment versus the placebo group, Difference in number of treatment responders (≥ 30% reduction in mean monthly headache days at weeks 5 – 8 post-intervention compared to baseline) in the treatment versus the placebo group., Difference in change from baseline in the mean monthly headache intensity in the treatment versus the placebo group., Difference in change from baseline in the mean monthly occurrence of cumulative hours per 28 days of moderate/severe pain in the treatment versus the placebo group., Difference in change from baseline in the mean monthly number of days with rescue medication in the treatment versus the placebo group., Migraine specific quality of life questionnaire | — |
Countries
Norway
Outcome results
None listed